This revenue range excludes revenue from Lucent Diagnostics testing, which is expected to be immaterial for 2024. The company also reaffirmed that it expects its research-use only business to achieve cash flow breakeven when it reaches revenue between $170M-$190M. The Company continues to expect GAAP gross margin percentage to be in the range of 57%-61%, and non-GAAP gross margin percentage to be in the range of 51%-55%. The company continues to anticipate 2024 cash usage to be approximately $30M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX: